Weight management treatment is moving quickly. In 2026, UK patients have new options, including the Wegovy® pill, the Foundayo tablet and higher doses of semaglutide injections, while treatments such as triple-agonist medications are still being studied. This guide gives a clear, factual overview of what that means for patients.
What’s New in Weight Loss 2026: Pills, Higher Doses, and Emerging GLP-1 Therapies
Oral semaglutide: the Wegovy® pill
The MHRA licensed the Wegovy pill (oral semaglutide 25mg) for weight management in the UK on 11 June 2026, following FDA approval in the United States. It is a once-daily tablet.
Results from the Phase III OASIS-4 trial show meaningful reductions in body weight compared with placebo, alongside improvements in cardiometabolic markers. The tablet is designed to survive digestion and deliver similar effects to injectable semaglutide.
Foundayo: a once-daily tablet
In August 2026 the MHRA approved Foundayo (orforglipron), another once-daily weight loss tablet. Unlike the Wegovy pill, it can be taken at any time of day without food or water restrictions. Read more in our guide to Foundayo.
Higher-dose semaglutide: Wegovy® 7.2mg
A 7.2mg once-weekly semaglutide injection is now available. Clinical studies suggest greater weight loss than lower doses, with safety and tolerability broadly comparable to the established 2.4mg dose. Careful dose titration and individual assessment remain key.
Emerging GLP-1 and multi-agonist therapies
Dual Agonists
Medications like Mounjaro (tirzepatide) combine GLP-1 and GIP agonism and are already available in the UK.
Other treatments in development
Several other oral and injectable medicines are in clinical trials. Approval timelines and UK availability for these are still uncertain.
Triple-Agonist Therapies (Triple-G)
Research continues into medications targeting three hormonal pathways simultaneously: GLP-1, GIP, and glucagon receptors, such as Retatrutide. Sometimes referred to in media as “triple-G,” these therapies are still being studied. Early data suggest strong weight-loss potential, but longer-term safety and efficacy data are still needed.
What this means for patients
- Patients now have a broader range of medical treatment options.
- Treatment decisions should still be based on individual response, medical history, and safety.
- Lifestyle support, including diet, activity and behavioural change, remains essential.
Looking ahead
2026 has already brought more flexibility in obesity treatment, with tablets, higher-dose injections and multi-agonist therapies expanding options. Clinicians and patients should stay updated as new evidence and approvals emerge.
Key takeaways
- The Wegovy® pill was licensed by the MHRA on 11 June 2026, and the Foundayo tablet was approved in August 2026.
- Higher-dose semaglutide (7.2mg) may provide an additional injectable option.
- New dual and triple-agonist therapies are in development, with availability dates expected to be clarified as evidence matures.
- Personalised treatment decisions remain essential, alongside lifestyle support.
Disclaimer & summary
This article is for information only and does not replace personal medical advice. Availability and approvals vary by country. Always speak to a qualified healthcare professional before starting or changing treatment.
2026 is shaping up to be an important year in weight management. Tablets, higher-dose injections and emerging dual and triple-agonist medicines may expand options for adults living with obesity. Clinical guidance remains essential for safe, effective, and personalised care.
